Intuitive Surgical Inc ISRG
We take great care to ensure that the data presented and summarized in this overview for INTUITIVE SURGICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ISRG
View all-
Vanguard Group Inc Valley Forge, PA31.9MShares$16.8 Billion0.29% of portfolio
-
Black Rock Inc. New York, NY30.1MShares$15.9 Billion0.31% of portfolio
-
State Street Corp Boston, MA15.1MShares$7.93 Billion0.31% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD14.6MShares$7.7 Billion0.83% of portfolio
-
Jpmorgan Chase & CO New York, NY10MShares$5.27 Billion0.4% of portfolio
-
Geode Capital Management, LLC Boston, MA7.51MShares$3.96 Billion0.3% of portfolio
-
Capital World Investors Los Angeles, CA7.41MShares$3.91 Billion0.58% of portfolio
-
Morgan Stanley New York, NY5.58MShares$2.94 Billion0.2% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa4.78MShares$2.52 Billion0.97% of portfolio
-
Franklin Resources Inc San Mateo, CA4.43MShares$2.34 Billion0.65% of portfolio
Latest Institutional Activity in ISRG
Top Purchases
Top Sells
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Insider Transactions at ISRG
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2024
|
Jamie Samath CFO and Head of Business Techn |
SELL
Open market or private sale
|
Direct |
270
-1.52%
|
$145,800
$540.15 P/Share
|
|
Dec 10
2024
|
Jamie Samath CFO and Head of Business Techn |
BUY
Exercise of conversion of derivative security
|
Direct |
270
+1.5%
|
$72,090
$267.03 P/Share
|
|
Nov 29
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
376
-3.3%
|
$202,664
$539.0 P/Share
|
|
Nov 29
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
376
+3.2%
|
$93,624
$249.61 P/Share
|
|
Nov 29
2024
|
Jamie Samath CFO and Head of Business Techn |
SELL
Open market or private sale
|
Direct |
188
-1.06%
|
$101,332
$539.0 P/Share
|
|
Nov 29
2024
|
Jamie Samath CFO and Head of Business Techn |
BUY
Exercise of conversion of derivative security
|
Direct |
188
+1.05%
|
$46,812
$249.61 P/Share
|
|
Nov 26
2024
|
Jamie Samath CFO and Head of Business Techn |
SELL
Open market or private sale
|
Direct |
108
-0.61%
|
$58,536
$542.06 P/Share
|
|
Nov 26
2024
|
Jamie Samath CFO and Head of Business Techn |
BUY
Exercise of conversion of derivative security
|
Direct |
108
+0.61%
|
$31,968
$296.51 P/Share
|
|
Nov 26
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
396
-3.47%
|
$214,632
$542.06 P/Share
|
|
Nov 26
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
396
+3.35%
|
$117,216
$296.51 P/Share
|
|
Nov 22
2024
|
David J. Rosa President |
SELL
Bona fide gift
|
Direct |
915
-0.43%
|
-
|
|
Nov 12
2024
|
Myriam Curet EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,466
-90.97%
|
$7,204,310
$535.96 P/Share
|
|
Nov 12
2024
|
Myriam Curet EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,466
+47.62%
|
$2,679,734
$199.78 P/Share
|
|
Nov 11
2024
|
Jamie Samath CFO and Head of Business Techn |
SELL
Open market or private sale
|
Direct |
269
-2.98%
|
$144,991
$539.89 P/Share
|
|
Nov 11
2024
|
Jamie Samath CFO and Head of Business Techn |
BUY
Exercise of conversion of derivative security
|
Direct |
269
+1.48%
|
$71,823
$267.03 P/Share
|
|
Nov 11
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
239
-2.12%
|
$128,821
$539.89 P/Share
|
|
Nov 11
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
239
+2.08%
|
$63,813
$267.03 P/Share
|
|
Nov 08
2024
|
Jamie Samath CFO and Head of Business Techn |
SELL
Open market or private sale
|
Direct |
22,903
-72.34%
|
$12,024,075
$525.0 P/Share
|
|
Nov 08
2024
|
Jamie Samath CFO and Head of Business Techn |
BUY
Exercise of conversion of derivative security
|
Direct |
22,903
+8.75%
|
$5,153,175
$225.82 P/Share
|
|
Nov 05
2024
|
David J. Rosa President |
SELL
Bona fide gift
|
Direct |
3,960
-0.92%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 546K shares |
|---|---|
| Grant, award, or other acquisition | 3.35K shares |
| Open market or private sale | 437K shares |
|---|---|
| Payment of exercise price or tax liability | 31.3K shares |
| Bona fide gift | 22.4K shares |